secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0001171843-24-005515
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech enters $3.87M ATM equity facility with H.C. Wainwright; terminates prior Canaccord agreement
--------------------------------------------------------------------------------

- Entered ATM agreement with H.C. Wainwright to sell up to $3.87M common shares at market prices; commission 3%.
- Terminated prior equity distribution agreement with Canaccord Genuity (dated March 2023) effective Oct 3, 2024.
- Under the Canaccord agreement, Edesa sold ~368,309 shares for ~$2.0M proceeds; no termination penalties.
- No obligation to sell all shares under the new ATM; company may suspend sales at any time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184324005515/0001171843-24-005515-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184324005515/f8k_100424.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-005515

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer